News
As an unplanned overall survival analysis of ivonescimab’s Keytruda head-to-head trial rocked the PD- (L)1xVEGF world, Akeso ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback